Associated with small intestinal bacteria overgrowth (SIBO) due to its production by C. di cile, C. stricklandii, C. lituseburense, C. subterminale, C. putrefaciens, and C. propionicum.

Associated with small intestinal bacteria overgrowth (SIBO) due to its production by C. di cile, C. stricklandii, C. lituseburense, C. subterminale, C. putrefaciens, and C. propionicum.

p-hydroxyphenyllactate is a marker of cell turnover. It is also a metabolite in tyrosine degradation and may be useful for studying disorders of tyrosine metabolism.

P-tau181 is a phosphorylated form of the tau protein that reflects Alzheimer's-type brain pathology. Measured in plasma (blood) or CSF, elevated levels indicate amyloid plaques and tau tangles in the brain. Normal range varies significantly by assay: Lumipulse ~under 0.95 pg/mL; Simoa ~under 2.0–2.25 pg/mL. P-tau181 is less accurate than p-tau217 but more widely available and well established. Always use the reference range on your own lab report.

P-tau217 is a phosphorylated form of the tau protein measured in blood plasma. Elevated levels indicate Alzheimer's-type amyloid and tau pathology in the brain. On the Lumipulse platform (the most widely used clinical assay), results below ~0.18–0.20 pg/mL are typically negative; above ~0.32–0.33 pg/mL are typically positive; values in between are indeterminate. Cutoffs are assay-specific — always use the reference range on your own report.

The P/E2 ratio describes the relationship between progesterone and estradiol levels, and is used clinically to ascertain dominance of one hormone compared to the other.

When it comes to diagnosing Lyme disease, a condition caused by the Borrelia burgdorferi bacteria, healthcare providers often rely on a combination of clinical evaluation, patient symptoms, and specific laboratory tests. One of the components sometimes found on a Borrelia test panel is the P100 biomarker. Understanding what this biomarker signifies and how it fits into Lyme disease diagnostics can shed light on the often-complex process of diagnosing this tick-borne illness.

What is the P100 Biomarker?

P100 is a protein antigen found in the Borrelia burgdorferi bacterium. This protein, along with others like P41, OspC, and others, is used to detect the presence of an immune response to Lyme disease. The P100 antigen, sometimes referred to as the 100 kDa protein, gets its name from its molecular weight. This protein becomes relevant in Lyme disease testing because it is associated with the immune response to the infection; when the immune system encounters Borrelia burgdorferi, it generates antibodies that specifically target bacterial antigens, including P100. Detecting antibodies against P100 can provide insight into a patient’s exposure to the Lyme-causing bacteria.

The Epstein-Barr Virus (EBV) p18 IgG marker is a vital component of the NeuralZoomer Plus panel from Vibrant Wellness, designed to assess neurological health and the risk of autoimmunity. EBV, a widespread herpesvirus, infects most people at some point in their lives, potentially leading to infectious mononucleosis. However, many individuals carry the virus asymptomatically. The p18 IgG marker specifically indicates the body's immune response to EBV, focusing on the production of Immunoglobulin G (IgG) antibodies against the virus's p18 protein—a component of the viral capsid antigen (VCA), essential for the virus's infection and replication processes.

The presence of IgG antibodies against EBV's p18 suggests a past or chronic infection, offering significant insights into a patient's immune system status and potential neurological or autoimmune disease risk factors. This testing is crucial, as chronic EBV infection is linked to various neurological conditions and autoimmune diseases. The NeuralZoomer Plus panel facilitates early detection and intervention, providing a personalized approach to prevent and manage neurological health issues. By including the EBV p18 marker, the panel offers a comprehensive view of the body's immune activity against EBV, essential for diagnosing and treating conditions with a potential viral cause.